Detalhe da pesquisa
1.
Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations.
Am J Hematol
; 99(6): 1172-1174, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38436141
2.
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Br J Haematol
; 197(1): 52-62, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34997766
3.
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
Eur J Haematol
; 109(1): 90-99, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35403752
4.
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
Br J Haematol
; 193(2): 346-355, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33368155
5.
Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
Br J Haematol
; 192(1): 137-145, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33022753
6.
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.
Haematologica
; 104(11): 2206-2214, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30923102
7.
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Haematologica
; 104(12): 2400-2409, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31073075
8.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
Ann Hematol
; 98(2): 321-330, 2019 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-30446802
9.
Is COVID-19 less severe in CML patients than in those with other haematological cancers?
Br J Haematol
; 196(3): 471-472, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34708401
10.
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
Br J Haematol
; 197(1): e1-e4, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34923623
11.
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.
Hematol Oncol
; 34(3): 154-60, 2016 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25469485
12.
Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations.
Haematologica
; 105(5): e225-e227, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31537692
13.
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance.
Leukemia
; 38(4): 796-802, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38424138
14.
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia.
Leuk Lymphoma
; : 1-6, 2024 Apr 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38652865
15.
Development of artificial bone marrow fibre scaffolds to study resistance to anti-leukaemia agents.
Br J Haematol
; 182(6): 924-927, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28771682
16.
FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
BMC Med Genomics
; 16(1): 172, 2023 07 26.
Artigo
Inglês
| MEDLINE | ID: mdl-37496024
17.
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.
Haematologica
; 102(8): e297-e299, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28495914
18.
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Nat Commun
; 13(1): 6922, 2022 11 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36376307
19.
Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.
Am J Hematol
; 91(11): E480-E481, 2016 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-27467708
20.
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.
Cancers (Basel)
; 13(19)2021 Sep 28.
Artigo
Inglês
| MEDLINE | ID: mdl-34638347